Ignite Creation Date:
2025-12-24 @ 6:39 PM
Ignite Modification Date:
2026-01-01 @ 11:42 AM
Study NCT ID:
NCT01267357
Status:
COMPLETED
Last Update Posted:
2010-12-28
First Post:
2010-12-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer
Sponsor:
Rambam Health Care Campus
Organization:
Study Overview
Official Title:
Expression of the P16 Protein in Serous Papillary Endometrial Cancer, and Its Clinical and Prognostic Significance
Status:
COMPLETED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
P16 is a tumor suppressor protein implicated in serous papillary endometrial carcinoma. Evidence from previous trials indicates that it may be used as a diagnostic biomarker distinguishing this disease from endometrioid endometrial cancer. Additional evidence points to its prognostic value.
The current study will evaluate p16 both as a diagnostic tool for serous papillary endometrial cancer and as a prognostic biomarker.
following anonymization, histology blocks will be microtomed and stained for P16 and P53 proteins.
Blocks from endometrioid endometrial cancer will be used as a control group.
The current study will evaluate p16 both as a diagnostic tool for serous papillary endometrial cancer and as a prognostic biomarker.
following anonymization, histology blocks will be microtomed and stained for P16 and P53 proteins.
Blocks from endometrioid endometrial cancer will be used as a control group.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: